7 articles in this category
You have a promising Morphium compound. The biomarker data from your primary phase 2 looks clean. Then the cross-study validaal comes back—and it is a...
You are watching the curve. It used to climb. 0.1 mg/kg gave 40% effect. 0.2 gave 65%. Now 0.3 barely reaches 70%. The slope is a shallow smear. Trans...
You have picked your primary endpoint. You have written it into the protocol. The clock is ticking. Then, six month in, a site coordinator asks a plai...
You run a morphium trial. Twelve weeks in, the active arm shows a 30% reduction in pain scores. The group is excited. But something feels off—maybe th...
It was a Tuesday morning, 7:43 AM. I was staring at a scatter plot of dissolution profiles from our lead Morphium formulation. One point sat alone, tw...
Every morphium trial confronts a quiet crisis at the protocol station: how to pick a control group that will not poison the results with bias. The tex...
You have a promising Morphium analog. The preclinical data looks solid. The group is ready. But the trial will fail before the primary syringe is unca...